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Abstract
Background: Preoperative radiochemotherapy followed by surgical removal of the rectum with total mesorectum
excision is the preferred treatment option for stages II and III rectal cancer. However, development of metastatic
disease is the main cause of death for these patients with 5-year disease-free survival rates of 56 %. Anti-epidermal
growth factor receptor (EGFR) targeted therapy is effective in metastatic rectal cancer, and human epidermal
growth factor receptor 2 (HER-2) signaling may mediate resistance to EGFR inhibitors. Moreover, preclinical data
support a synergistic effect of EGFR inhibition with radiation therapy.
Methods/design: This Bayesian phase II trial with adaptive randomization was designed to assess the efficacy of
adding lapatinib, a dual inhibitor of EGFR and HER-2, to standard radiochemotherapy with capecitabine in stages
II and III rectal cancer.
Discussion: The results of this trial will provide evidence of the feasibility and efficacy of the combination of
lapatinib-capecitabine as radiosensitizers and explore potential predictive biomarkers for response to this novel
neoadjuvant approach to resectable rectal cancer.
Trial registration: EudraCT 2013-001203-36. Registered on 13 December 2013.
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Background
Colorectal cancer is the third most incident cancer and
the second most common cause of cancer death in Europe
[1]. Cancer of the rectum accounts for a third of colorectal
cancer cases [2] with 5-year survival rates ranging from
28–55 % in men and 30–64 % in women [3].
Current treatment options for patients with rectal cancer
include surgery, radiation therapy, chemotherapy, and tar-
geted systemic therapy. The choice of therapy depends on
disease stage, overall health status, and patient preferences.
For localized disease, surgical removal of the rectum with
total mesorectum excision is the surgical technique of
choice, with an estimated overall survival of 86 % and a
local recurrence rate of 9 % at 2 years [4]. However, the use
of radiotherapy before surgical resection decreases local re-
currence rate and impacts overall survival [5]. Moreover,
the addition of fluoropyrimidine-based chemotherapy to
preoperative radiotherapy further improves local control
and pathologic response rates [6]. In patients treated with
preoperative radiochemotherapy, whenever downstaging
occurs, the risk of death due to cancer is significantly
reduced [7]. Despite these therapeutic improvements,
patients with localized rectal cancer have 5-year disease-
free and overall survival rates of about 59 % and 67 %,
respectively [8, 9]. For these patients, development of
metastatic disease is the main cause of death.
Capecitabine is a non-cytotoxic fluoropyrimidine carba-
mate, which functions as an orally administered precursor
of the cytotoxic agent 5-fluorouracil. Capecitabine is active
as a single agent in colorectal cancer, and it is approved
for the adjuvant and palliative treatment of patients with
colorectal cancer [10]. Its value as a radiosensitizer in rec-
tal cancer has been established by several phase II trials,
with pathologic response rates that range from 7–38 %
[11–15]. In a phase III non-inferiority trial, radiochemo-
therapy with capecitabine was shown to be non-inferior to
5-fluorouracil radiochemotherapy, with survival rates of
76 % at 5 years [16]. Taken together, these data and the
more comfortable administration regimen of capecita-
bine compared to infusional 5-fluorouracil make it the
preferential agent for the neoadjuvant treatment of
patients with rectal cancer.
Colorectal cancer frequently overexpresses epidermal
growth factor receptor (EGFR) [17]. Ligand binding to the
extracellular portion of the receptor promotes homodi-
merization or heterodimerization and subsequent activa-
tion of the receptor. This leads to increased cell growth,
proliferation, and mobility, decreased apoptosis, and
stimulation of angiogenesis. Currently available drugs
targeting the EGFR include monoclonal antibodies
(e.g., cetuximab and panitumumab) and small molecule
tyrosine kinase inhibitors (e.g., gefitinib, erlotinib, and
lapatinib). In metastatic colorectal cancer, cetuximab and
panitumumab were shown to be clinically effective
[18–23]. Resistance to anti-EGFR antibodies may be
mediated by HER-2, since the addition of anti-HER-2
targeting agents to cetuximab is able to overcome this
resistance [24, 25]. These data support the development
of therapeutic strategies targeting both EGFR and HER-
2 in colorectal cancer. Additionally, targeting the EGFR
pathway during neoadjuvant radiochemotherapy is as-
sociated with an increased number of cells in the G1
phase of the cell cycle (the most radiosensitive phase)
and increased apoptosis, and prevents repair of DNA
damage induced by radiation exposure, thus suggesting
a possible synergistic effect of EGFR inhibition with
radiation therapy [26, 27]. This strategy has been ex-
plored with cetuximab and gefitinib in combination
with fluoropyrimidine-based radiochemotherapy in the
phase I/II setting with disappointing results [28–30].
However, all these studies were conducted before the
predictive role of RAS mutations in anti-EGFR treated
patients was recognized; therefore, they may have been
underpowered to detect a clinically relevant improve-
ment for this therapeutic strategy.
Lapatinib is a small molecule dual tyrosine kinase in-
hibitor targeting both EGFR and HER-2. Preclinical
studies have shown that lapatinib is active in colorectal
cancer cell lines [31, 32], and its radiosensitizing proper-
ties have also been demonstrated in preclinical models
[33, 34]. In treating metastatic colorectal cancer, lapati-
nib has been shown to be well tolerated, both as a single
agent and in combination with chemotherapy, but with
limited activity [35–38]. However, no population enrich-
ment strategy based on tumor characteristics was imple-
mented, and these trials may have been underpowered
to identify any clinically relevant activity. Considering
the clinical value of anti-EGFR therapy in RAS wild-type
colorectal cancer [19–23, 39] and the theoretical advan-
tage of anti-EGFR treatment during radiotherapy [26, 27]
together with the data suggesting that dual inhibition of
EGFR and HER-2 may be synergistic [31, 32], one can
hypothesize that lapatinib is an ideal candidate for opti-
mizing the neoadjuvant treatment of rectal cancer.
A randomized phase II trial with an adaptive Bayesian
randomization design is proposed to assess the efficacy
and safety of the tyrosine kinase inhibitor lapatinib
combined with the fluoropyrimidine analog capecita-
bine as radiosensitizers in patients with clinical stage
II/III resectable rectal cancer without activating RAS
mutations.
Methods/design
This single-center phase II trial is designed with an
adaptive Bayesian randomization, which will allocate eli-
gible patients to either lapatinib-capecitabine (arm A) or
capecitabine (arm B) during standard radiation treatment
for rectal cancer. The first 20 patients will be allocated at a
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1:1 ratio. From that time point onward the randomization
of a patient to either arm will be weighted by the updated
estimate of the success probability in each arm, hence
giving patients a higher chance of being allocated to
the current most efficacious arm of the trial. The trial
is designed to be stopped earlier if evidence of superiority
of one arm over the other, futility, or unacceptable toxicity
in arm A is identified.
Population and setting
The trial will be implemented at Instituto Português de
Oncologia do Porto Francisco Gentil, EPE, where patients
will be considered eligible for the trial based on the
following criteria.
Inclusion criteria
Each patient must meet all of the following inclusion
criteria to be enrolled in the study:
1. Age of 18 years or above
2. Diagnosis of adenocarcinoma of the rectum with the
primary malignant lesion located between the
dentate line up to 10 cm of the anal verge by
endoscopic examination
3. Absence of activation mutation in KRAS exons 2
(codons 12 and 13), 3 (codons 59 and 61),
and 4 (codons 117 and 146) and NRAS exons 2
(codons 12 and 13), 3 (codons 59 and 61),
and 4 (codons 117 and 146)
4. Clinical stage II or III disease, according to
American Joint Committee on Cancer Staging
classification, 7th edition [40]. For clinical staging,
the following procedures must have been conducted
within 4 weeks of treatment allocation:
(a) Clinical history and physical examination
(b) Endoscopic ultrasound of the primary lesion
(c) Thoracic, abdominal, and pelvic computed
tomographic (CT) scan
5. Clinically judged to be able to undergo curative
resection of the rectal neoplasm despite preoperative
radiochemotherapy
6. Clinically judged to be able to undergo pelvic
radiation therapy to a total dose of 50.4 Gy
7. Provision of signed informed consent
Exclusion criteria
Patients meeting any of the following exclusion criteria
are not to be enrolled in the study:
1. Absence of baseline histological sample of the
primary tumor
2. Pregnant or lactating women
3. Unwillingness or inability to comply with effective
contraception, if the patient is fertile.
4. Impaired renal function defined as creatinine
clearance <60 mL/min according to the
Cockcroft-Gault formula
5. Impaired hematological function as defined by any
of the following on pretreatment evaluation:
(a) Hemoglobin concentration <10.0 g/dL,
(b) Absolute neutrophil count <1500/μL
(c) Platelet count <100,000/μL
6. Impaired hepatic function defined by any of the
following on pretreatment evaluation:
(a) Serum level of aspartate aminotransferase
>1.5 × ULN,
(b) Serum level of alanine aminotransferase
>1.5 × ULN,
(c) Serum level of alkaline phosphatase >1.5 × ULN,
(d) International normalized ratio >1.5
(e) Serum concentration of total bilirubin
>1.5 × ULN
7. Symptomatic heart failure or a left ventricular
ejection fraction (LVEF) below the institution’s lower
limit of normality (LLN) as assessed through
equilibrium radionuclide angiography
8. Known intolerance to any of the study drugs.
9. Known dihydropyrimidine dehydrogenase (DPD)
deficiency
10.Concurrent treatment with CYP3A4 inducers
(as detailed in the following section)
11.Concurrent treatment with CYP3A4 inhibitors
(as detailed in the following section)
12.Likely inability to comply with the protocol
or cooperate fully with the investigator and
site personnel
13.Current enrollment in another clinical trial.
Trial procedures and study interventions
Recruitment and enrollment for this study will be from
the institution’s local practice or referrals from other
physicians. All trial-related procedures and interventions
will be performed according to the predefined schedule
of events (Table 1). Before any study-related procedure,
each patient will provide written informed consent, un-
less that procedure was performed as part of the pa-
tient’s standard medical care and is eligible for trial
enrollment. Prior to study treatment a screening period,
no longer than 28 days, will be considered. During this
period, eligibility will be assessed and tumor tissue pro-
cured for biomarker analysis. Eligible patients will be
randomly allocated to an experimental arm (arm A),
which will test the addition of lapatinib to radiochemo-
therapy with capecitabine or a control arm (arm B),
which will consist of standard radiochemotherapy with
capecitabine. Patients allocated to arm A will undergo
an initial lead-in period of 14 days with lapatinib before
radiochemotherapy. At the end of the lead-in period,
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Table 1 Schedule of events
Screening Random
allocation (a)
Treatment period EOT Surgery EOS
Day -14 (b) Day -7 Day 1 (c) Day
8 ± 3 days
Day
15 ± 3 days
Day
22 ± 3 days
Day
29 ± 3 days
Day
36 ± 3 days
Day






Inclusion/exclusion criteria X X
Demographics X
Medical history X
Concomitant medications X X X X X X X X X X X
Adverse events X X X X X X X X X
Physical examination X X
Vital signs X X X X X X X X X X X
Weight X X X X X X X X X X X
Height X
ECOG performance status X X X X X X X X X X X
Electrocardiogram (12-lead) X X X
MUGA X X X
Hematology X X X X X X X X X X X
Serum chemistries X X X X X X X X X X X
Hemostasis X





Tumor sampling X X(c) X
Lapatinib (arm A) 1 250 mg/d until the last day of radiotherapy
Capecitabine
(arms A and B)
825 mg/m2 twice daily from first to last day of radiotherapy
Radiation therapy 50.4 Gy in 28 fractions of 1.8 Gy, 5 days per week
EOT end of treatment visit, EOS end of study visit
(a) Within 4 weeks of screening visit
(b) Not more than 3 days before day -14 in arm A or more than 14 days before day 1 in arm B. In arm B, random allocation visit procedures are valid for day 1 visit if <7 days have elapsed









patients in arm A will have a tumor biopsy performed
for biomarker assessment. As lapatinib is a substrate for
CYP3A4, inducers and inhibitors of this enzyme are pro-
hibited from screening through discontinuation from
study, and a predefined wash-out period prior to ran-
dom allocation has been set (Table 2). Seven to eight
weeks after completion of radiochemotherapy, patients
will be surgically treated. For the duration of the trial,
no other concurrent anticancer therapy or investiga-
tional agents are allowed. During the trial, neither pa-
tients nor treating physician will be blinded to treatment
interventions.
Lapatinib
Lapatinib, 250-mg tablets, will be self-administered, on
an empty stomach (either 1 h before or after a meal),
with water, once daily at approximately the same time
each day, at a dose of 1250 mg/d. Treatment with
lapatinib will be initiated 14 days prior to radiation ther-
apy (lead-in period) and continued for the duration of
radiation therapy. Patients will be instructed not to take
lapatinib with grapefruit or grapefruit juice. Moreover,
patients will be instructed that if they vomit any time
after taking a dose, they must not “make it up” with an
extra dose, but instead resume dosing with the next
scheduled daily dose. Any missed dose will not be re-
placed; the dosing should resume with the next scheduled
daily dose. Patients will be required to return all used, un-
used, and/or partially used bottles of lapatinib, and the
number of remaining tablets will be documented and re-
corded to assess compliance.
Capecitabine
Capecitabine, 150-mg tablets and 500-mg tablets, will be
self-administered at a dose of 825 mg/m2 (dose rounded
to the nearest possible combination of the available
tablet formulations) twice daily, within 30 minutes of a
meal, with water, for the duration of radiotherapy.
Patients will be required to return all used, unused, and/
or partially used blister packs of capecitabine at the next
study visit. The number of tablets remaining will be
documented and recorded to assess compliance.
Radiation therapy
Patients will be treated with megavoltage energy to a
total treatment dose of 50.4 Gy to the clinical target
volume. This treatment will be administered in 1.8-Gy
daily fractions, 5 days per week. The treatment technique
will be decided by a senior radiotherapist with expertise in
rectal cancer treatment. The following techniques will be
available: 3D conformal external beam radiation (3D-RT),
intensity modulated radiotherapy (IMRT), and volume
modulated arc therapy (VMAT). The choice of technique
will depend on the need to protect the organs at risk for
increased toxicity with radiation treatment based on the
planning CT scan. The planning CT scan will image the
lower abdomen and pelvis, from first lumbar vertebra to
3 cm below the buttocks soft tissue projection, with 2.5-
mm-thick slices. For both the planning CT scan and treat-
ment, the patient will be in a supine position, with head
and knee support and hands resting on the thorax with
the bladder comfortably full [41]. Volume delineation and
dose prescription will be done according to the guidelines
set forth by International Commission on Radiation Units
(ICRU) Reports 50 and 62 for 3D-RT and ICRU Report 83
for IMRT or VMAT. The primary tumor and regional
lymph nodes will be included in the treatment volumes
[42–44]. The following volumes will be considered: gross
tumor volume (GTV), which includes the rectal tumor
and suspicious lymph nodes; clinical tumor volume 45 Gy
(CTV45), which includes the rectal tumor and the re-
gional lymph nodes (delimited superiorly by the common
Table 2 CYP3A4 inducers and inhibitors
Drug class Agent Wash-out
CYP3A4 inducers









Cortisone (>50 mg), hydrocortisone























GI agents Cimetidine, aprepitant
Others Grapefruit, grapefruit juice
Amiodarone 6 months
Miscellaneous
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iliac arteries bifurcation and inferiorly by the obturator
canal); the planned target volume 45 Gy (PTV45), which
includes the CTV45 with a 1-cm external margin except
when that margin is the skin; the clinical tumor volume
50.4 Gy (CTV50.4), which includes the GTV and the en-
tire mesorectum and presacral region at involved levels
and a 2-cm cephalad and caudal margin beyond any suspi-
cious lymph node, and for tumors located at the anorectal
junction, the CTV50.4 will include the GTV and a 1-cm
anterolateral and posterior margin in addition to the
above mentioned cephalad and caudal margin; and the
planned target volume 50.4 Gy (PTV50.4), which includes
the CTV50.4 with a 1-cm margin, except at the skin.
During treatment planning the following organs will
be considered at risk of unacceptable toxicity during
pelvic radiation: bladder, small intestine, and femurs
(head of femur). To protect against this risk, during
treatment planning, dose-volume histograms for these
organs will be independently calculated to ensure that
the dose constraints set forth in Table 3 for each of the
organs at risk are abided by [45–47].
Surgery
For all included patients, surgical treatment will be per-
formed 7 to 8 weeks after the end of radiation therapy.
The choice of surgical technique will depend on preopera-
tive assessment by a senior surgeon trained in rectal cancer
surgery. Total mesorectum excision will be recommended.
Management of trial interventions
During treatment, all patients will be observed weekly to
assess toxicity. Patients are allowed to receive full sup-
portive care therapies concomitantly during the study.
Summary recommendations for dose modification due
to treatment emergent adverse events are defined and
outlined in Table 4. No individual lapatinib dose reduction
or dose escalation will be allowed to manage treatment-
related adverse events. In the event of excess toxicity at a
dose level of 1250 mg/d of lapatinib, the trial will be
stopped and restarted with lapatinib dosed at 1000 mg/d.
If a patient requires holding of radiation treatment for 2
or more weeks to manage any adverse event, radiation
treatment will be discontinued. In case of radiation
treatment interruption, the total dose will be adjusted
according to a biological equivalent dose calculation
[48]. Any of the study interventions (lapatinib, capecita-
bine, and radiation therapy) may be discontinued if a
patient experiences treatment emergent adverse events
judged by the investigator to outweigh its benefits.
Treatment with the study drug may be discontinued for
any of the following reasons: protocol violation, study
termination by the sponsor, loss to follow-up, or death.
Additionally patients may discontinue therapy at any time.
Patients who discontinue any of the study drugs prior
to surgical treatment may remain in the study and
undergo radiation therapy (if this was not the cause of
study drug discontinuation) and surgical treatment as
per protocol. Patients who discontinue study drug due
Table 3 Dose-volume constraints
Organ at risk Dose restriction
Bladder V40 < 50 %
V45 < 30 %
Small intestine No more than 180 cc above 35 Gy
No more than 100 cc above 40 Gy
No more than 65 cc above 45 Gy
Femoral head V25 < 45 %
V40 < 40 %
V50 < 10 %
Table 4 Summary of dose modification guidelines
Adverse event (CTCAE v4.0) Lapatinib Capecitabine Radiation
Hematology: neutrophils or platelets
Grade –2: Continue Hold 7 daysa Continue
Grade ≥3: Hold 7 daysa Holdb
Dermatology: rash
Grade –3: Hold 7 daysa Not applicable
Dermatology: irradiated skin
Grade ≥3: Not applicable Holdb
Dermatology: palmar-plantar erythrodysesthesia
Grade ≥2: Not applicable Hold 7 daysa Not applicable
Gastroenteroloy: diarrhea





>20 % from baseline and




ALT > 3 × ULN AND ALT
< 5 × ULN
Continue Not applicable
ALT > 3 × ULN AND ALT
> 5 × ULN for ≥2 weeks
Discontinue
ALT > 3 × ULN AND ALT
< 5 × ULN for > 4 weeks
ALT > 3 × ULN AND bilirubin
> 2 × ULN (>35 % direct)
ALT > 3 × ULN AND ALT
> 8 × ULN
ALT > 3 x ULN AND signs
and symptoms of hepatitis
or hypersensitivity
aRechallenge if grade 0–1
bRestart if grade 0–2
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to a discontinuation of radiation therapy and are deemed
surgically eligible will be surgically treated as per local
standard of care. Patients who discontinue study drug
will not be replaced.
Follow-up
The end of treatment visit will be performed approxi-
mately 14 days after the last dose of radiochemotherapy.
The end of study visit will be performed 30 days after
the surgical intervention. In the event a patient develops
any study-related toxicity, he will be followed until its
resolution or clinical stabilization.
Tumor specimen management
Biopsy fragments will be immediately placed in buffered
formalin and allowed to be fixed for 24–48 h. Then, the
specimen will be processed overnight for paraffin inclusion.
Four-micrometer-thick sections will be obtained from each
block, at four levels, and stained with hematoxylin and
eosin for histopathological assessment.
The surgical specimen will be delivered to the patholo-
gist fresh and unopened immediately after resection. After
inspection and recording of any area of perforation, the
non-peritonealized resection margin should be carefully
inked. The specimen should then be opened from its
anterior surface, excepting the area of the tumor, which
should be left unopened to allow for adequate documenta-
tion of the circumferential radial margin (CRM). A foam
or absorbent paper will then be passed through the re-
sidual lumen at the tumor site to aid the penetration of
the fixative. The specimen will be allowed to fix in buffered
formalin for 24–48 h before further dissection, description,
and sampling. The specimen will be sliced transversely
at 3–4 mm intervals within a range of 3 cm from the
tumor, both proximally and distally. At a minimum, tis-
sue sampling should include four blocks of the tumor,
disclosing the deepest level of invasion, involvement of
serosal surface or any adjacent organ, and extramural
vein invasion; a block from the closest distance of the
tumor or extramural deposit or tumor in a lymph node
to the non-peritonealized resection margin; a block
from the proximal and the distal margins (one each); a
block from the transition between the tumor and adja-
cent normal mucosa; a block from normal mucosa; all
lymph nodes identified; any other macroscopic abnor-
mality. If no definite residual tumor can be recognized,
the whole scarred area will be blocked for histopatho-
logical evaluation. Assessment of pathologic response will
be done according to EURECA-CC2 guidelines [49].
RAS mutational analysis
Hematoxylin and eosin stained slides will be carefully
reviewed by a pathologist to delimit areas with >50 %
tumor cells, and adjacent tissue sections will be obtained
from formalin-fixed paraffin-embedded tissue for DNA
extraction. Specific primers will be used to amplify a
92-bp amplicon of KRAS (exon 2, 3, or 4) or NRAS
(exon 2, 3, or 4), which will then be analyzed by high
resolution melting (HRM) to screen for mutations. In
cases positive by HRM, KRAS exons 2 (codons 12 and
13), 3 (codons 59 and 61), and 4 (codons 117 and 146)
and NRAS exons 2 (codons 12 and 13), 3 (codons 59
and 61), and 4 (codons 117 and 146) will be identified
by SNaPshot, which is based on the dideoxy single-base
extension of an unlabeled oligonucleotide primer. Frag-
ment analyses will be done by capillary electrophoresis.
Only patients without KRAS (exon 2, 3, or 4) or NRAS
(exon 2, 3, or 4) mutations will be enrolled.
Biomarker assessment
EGFR gene amplification and HER-2 gene amplification
will be analyzed by fluorescence in situ hybridization on
4-μm thick sections of a representative formalin-fixed
paraffin-embedded tissue block. Commercial probes will
be used: a test probe that targets EGFR and a control
probe for chromosome 7 centromere (CEP7) (Vysis), and
a test probe that targets HER-2 and a control probe for
chromosome 17 centromere (CEP17) (QBiogene). Slides
and probes will be codenatured, and hybridization will
take place overnight. After post-hybridization washes,
slides will be counterstained with DAPI. Fluorescent
images will be sequentially captured with a Cohu 4900
CCD camera, using an automated filter wheel coupled
to a Zeiss Axioplan fluorescence microscope and a
CytoVision system. Gene amplification will be scored
when a ratio EGFR/CEP7 or HER-2/CEP17 is greater than
or equal to 2.0 in a minimum of 60 cancer cell nuclei.
EGFR, protein kinase (AKT), and mitogen-activated
protein kinase (MAPK) phosphorylation status and Ki-
67 will be assessed by immunohistochemical analysis of
paraffin-embedded, formalin-fixed tumor tissue. Four-μm
sections will be cut and placed in silanized slides. Immu-
nostaining will be performed using a polymer method
(BrightVision Poly-HRP-Anti Ms/Rb/Rt IgG, Immuno-
Logic, Duiven, The Netherlands). After dewaxing the sec-
tions, endogenous peroxidase activity will be inhibited
with freshly prepared 0.5 % hydrogen peroxide in distilled
water for 20 min. Antigen retrieval will be performed with
EDTA buffer, pH 8, for 40 minutes. Incubation with pri-
mary antibodies for phosphorylated EGFR (clone Tyr1173
e 53A5), phosphorylated AKT (clone Ser473 e D9E), phos-
phorylated MAPK (clone Erk1/2,Thr202 e Tyr204), and
Ki-67 (clone MIB-1, Dako, Glostrup, Denmark) will be
performed overnight at 4 °C, at dilution 1:250, in 1 %
bovine serum albumin (BSA) in phosphate-buffered sa-
line (PBS). All incubations will be performed in a hu-
midified chamber. Sections will be developed with a
peroxidase substrate solution (0.05 % 3,3-diaminobenzidine
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tetrahydrochloride, 0.01 % H2O2 in PBS), counterstained
with hematoxylin, dehydrated, and mounted. Appropriate
positive and negative controls will be used. Assessment of
immunoexpression will be performed by light microscopy
at × 400 magnification by a senior pathologist.
Statistical considerations and quantitative analyses
Study endpoints
The primary endpoint is pathologic complete remission
(pCR). Pathologic complete remission will be determined
on the surgical specimen and defined according to the
guidelines recommended by the EURECA-CC2 consen-
sus [2] by a pathologist blinded to the treatment arm.
The secondary endpoint will be the safety profile of the
combination lapatinib-capecitabine and radiation therapy
in the preoperative setting of patients with resectable rectal
cancer assessed by the identification of adverse events and
serious adverse events coded with the National Cancer
Institute’s Common Terminology Criteria for Adverse
Events (CTCAE), version 4.0. An adverse event is defined
as any undesirable event associated with the use of a drug,
whether or not considered drug related, and includes any
side effect, injury, toxicity, or sensitivity reactions, or any
undesirable clinical or laboratory event not normally ob-
served in the patient. The following definition of serious
adverse event is used: any adverse event that results in
death, or is life-threatening, or results in persistent or
significant disability or incapacity, requires or prolongs
hospitalization, or results in a congenital abnormality
or birth defect, or results in any other medically im-
portant condition, or an adverse event as a result of an
overdose, or is a drug overdose (defined as ≥25 % in-
crease in dose over the protocol-specified dose or more
doses are given in a cycle).
Additionally the following exploratory endpoints will
be addressed: frequency of and predictive value for the
primary endpoint of EGFR amplification status, HER-2/neu
amplification status, and predictive value for the primary
endpoint of inhibition of EGFR and EGFR downstream
proteins on the 14th day of treatment in patients allocated
to arm A (MAPK, AKT).
Determination of sample size
The trial’s objective is to show the superiority of the
lapatinib and capecitabine combination (arm A) over the
standard capecitabine (arm B). Thus, the null hypothesis
is defined as H0: pB ≥ pA, where pA and pB are the
probabilities of a pCR for arms A and B, respectively.
The expected sample size calculations were conducted
in the context of a Bayesian adaptive randomization de-
sign, with stopping rules for early evidence of efficacy/
futility and evidence of toxicity. These calculations are
based on simulated trial results, which require presetting
maximum and minimum total sample size, minimum
number of patients fairly randomized to each arm, mini-
mum probability of randomization for each arm, prior
distributions for the treatment effect, and stopping rules
for efficacy/futility.
We chose a maximum of 80 patients, based on the
feasibility of patient’s accrual during the proposed study
period. A minimum of 30 patients should be enrolled in
the study before stopping the trial due to early evidence
of efficacy/inefficacy. However, accrual may stop before
the enrollment of 30 patients if there is evidence of toxicity,
as defined below. The first 20 patients enrolled in the study
will be fairly (non-adaptively) randomized to both arms.
During the adaptive randomization phase, the minimum
probability of randomization for each arm is set at 0.1.
For arm A, a non-informative prior for treatment effect,
i.e., pA ~Uniform (0,1), and for arm B, a moderate in-
formative prior for treatment effect pB ~ Beta (1.2, 8.8) are
used, as shown in Figs. 1 and 2, respectively.
The trial will be stopped for efficacy if the probability
of one arm being superior to the other is greater than
0.95 and for futility if the same probability is less than
0.05. Additionally, the trial stops for futility if the prob-
ability of arm A having an effect greater than 0.2 is less
than 0.05.
Fig. 1 Prior distribution for arm A
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Based on the previous setup, expected sample sizes
were computed for three different scenarios, based on
10,000 simulations of trial results:
I. pA = 0.30 and pB = 0.12
II. pA = 0.25 and pB = 0.12
III.pA = 0.12 and pB = 0.12
For scenario I, the expected sample size is 50 with 34
patients enrolled in arm A and 16 in arm B. The prob-
ability of choosing arm A as superior is 82 % (equivalent
to the power concept in the frequentist framework), and
the probability of early stop due to efficacy is 78 %. The
expected trial length is 13 months. For scenario II, 56
patients are expected to enroll in the trial with 37 pa-
tients in arm A and 29 in arm B. The probability of
identifying arm A as superior is 63 % (equivalent to the
power concept in the frequentist framework), and the
probability of early stop due to efficacy is 64 %. The ex-
pected trial length is 15 months. Finally, if no differences
exist between the two arms (scenario III), the expected
sample size is 60 (30 each arm). The probability of
choosing one of the arms as superior is 12 % (equivalent
to the probability of type I error in the frequentist
framework). The expected trial length is 16 months.
Randomization and stratification
The first 20 patients will be enrolled to arm A or B
based on a pretrial 1:1 random allocation list generated
by the trial statistician and made available to the re-
search team in sealed envelopes. After the first 20 pa-
tients, the statistician will provide the randomization
result for each patient according to the adaptive design.
If a patient discontinues participating in the study, his/her
randomization code will not be reused, and the patient
will not be allowed to re-enter the study.
Quantitative analysis
The following patient populations will be considered for
analysis:
 Intention-to-treat (ITT) population: the ITT
population is defined as all patients who are
randomized. Patients in this population will be
analyzed according to the treatment they were
randomized to receive, regardless of any errors
of dosing.
 Safety population: the safety population will be
assessed per treatment arm. For arm A it includes
all patients who have completed at least one
administration of lapatinib, irrespective of
starting treatment with capecitabine
(safety population in arm A). For arm B it
includes all patients allocated to arm B
and who completed at least one administration of
capecitabine (safety population in arm B).
 Per protocol (PP) population: the PP population
includes all patients who started the allocated
treatment and have been submitted to surgical
treatment.
 Exploratory subgroup analysis (ESA) population:
the ESA population includes patients with complete
data for the exploratory biomarkers who did not
have any major protocol violation.
All available efficacy and safety data will be included in
data listings and tabulations. However, for primary end-
point analysis any missing information regarding the end-
point (loss to follow-up or death prior to surgery and
refusal to undergo surgery) will be assumed as absence of
pathologic complete response. The impact of this imput-
ation will be tested with a sensitivity analysis. For assess-
ment of the stopping rule of toxicity, loss to follow-up
(after all efforts made to assess the reason for it have failed)
will be considered to be due to a serious adverse event.
Demographic and baseline characteristics including
gender, age, weight, height, clinical stage (American Joint
Committee on Cancer’s 7th edition cTN status [40]),
EGFR and HER-2 amplification status, and other parame-
ters, as appropriate, will be summarized by treatment
groups using descriptive statistics.
Fig. 2 Prior distribution for arm B
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The proportion of pCR of each arm will be described
and the efficacy of one arm over the other estimated by
the posterior probability of superiority and its 95 %
credible interval. The trial will be stopped for efficacy if
the posterior probability of one arm being superior to
the other is greater than 0.95 and for futility if the same
probability is less than 0.05. Additionally, the trial stops
for futility if the probability of arm A having an effect
greater than 0.2 is less than 0.05. The posterior prob-
ability of superiority of arm A over arm B will be con-
tinuously calculated after the 30th patient outcome is
known.
Adverse events will be described as absolute number
of patients presenting any given adverse event during
treatment, its proportion, and respective 95 % credible
intervals. Data will also be summarized as total number
of patients presenting at least one serious adverse event
and its proportion. For analysis of serious adverse
events, a summary posterior probability of a serious
adverse event and its 95 % credible interval will be
calculated. Patient accrual for arm A will be stopped for
toxicity if there is evidence of a serious adverse event
posterior probability (SAEPP) greater than 25 %. A con-
servative threshold of 0.5 will be used for the posterior
probability of toxicity, meaning that the trial stops with
moderate evidence (50 %) of SAEPP >25 % for arm A.
A non-informative prior (Beta (1, 1)) for the proportion
of toxic events was chosen. The boundary at each step
is plotted in Fig. 3. Should this toxicity boundary be
identified for arm A, accrual to the trial is interrupted
for excess toxicity at a lapatinib dose level of 1250 mg/d.
The trial will then restart with lapatinib at a dose level of
1000 mg/d in arm A, and the data from patients pre-
viously randomized to arm B will be used to adjust the
prior distribution of pB necessary for random treatment
allocation in the Bayesian framework previously defined.
In this latter setting, should the toxicity boundary be
crossed, accrual to the trial is stopped for toxicity and the
combination of lapatinib with capecitabine as radiosen-
sitizer will be considered too toxic for further study.
Biomarkers will be described as the proportion of pa-
tients with the given biomarker present in the respective
arm and their 95 % credible intervals. Identification of
predictive biomarkers will be performed through logistic
regression analysis. The model will test the association
between activation of EGFR pathway at baseline and
pCR (between group analyses) and the discriminatory
ability of its inhibition on pCR on arm A (within group
analysis). The following biomarkers will be included in
the model: EGFR amplification; HER-2/neu amplifica-
tion; MAPK phosphorylation status; AKT phosphoryl-
ation status; EGFR phosphorylation status at baseline
(between group analysis) and at baseline and on day 14
biopsy specimens for patients in arm A (within group
analysis). Odds ratios will be presented with their 95 %
credible intervals, and the c-statistics (area under the re-
ceiver operating characteristic curve) will be computed.
Ethical considerations
The protocol has been written, and the study will be
conducted according to the ICH Harmonized Tripartite
Guideline on Good Clinical Practice. All patients will be
informed about the aims of the study, trial procedures,
possible hazards and adverse events, the mechanism of
treatment allocation, and procedures to ensure patient
data confidentiality before enrollment.
The trial was submitted for ethical review by Portugal’s
National Ethics Committee for Clinical Research and was
approved on 7 February 2014, deliberation number 2014-
RP-02-11.
During the trial, if a protocol amendment is deemed
necessary and may significantly affect the safety of pa-
tients, the scope of investigation, or the scientific quality
of the study, a prior favorable opinion from Portugal’s
National Ethics Committee for Clinical Research and
approval from the Portuguese National Authority of
Fig. 3 Boundary for early stop due to toxicity
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Medicines and Health Products will be sought before
implementation. If a protocol amendment affects only
administrative aspects of the study, both the Portuguese
National Ethics Committee for Clinical Research and
Portuguese National Authority of Medicines will be noti-
fied of such administrative changes, but prior approval
will not be procured.
Clinical trial insurance has been taken out according
to Portuguese law by the sponsor.
Discussion
To our knowledge, this is the first trial to assess the effi-
cacy of dual inhibition of EGFR and HER-2 as a radiosen-
sitizer in resectable rectal cancer. The trial is designed to
include an enriched population of patients with KRAS
and NRAS wild-type rectal cancer due to evidence of lack
of benefit from anti-EGFR strategies in KRAS or NRAS
mutated colorectal tumors. However, the role of KRAS or
NRAS mutations in localized rectal cancer is uncertain.
There is no information on whether this subgroup of
rectal cancer patients have a different prognosis com-
pared to patients with activating mutations nor if ab-
sence of mutation in KRAS or NRAS is predictive of
response to standard radiochemotherapy. Thus, a ran-
domized trial with an active comparator was needed to
answer this question. The choice of a randomized adap-
tive Bayesian design allows an optimized sample size as
well as a concurrent comparator. This design optimizes
the trial’s sample size and protects eligible patients
from randomization to a weakly performing arm, thus
improving our ability to decide whether further study
of lapatinib in this setting is warranted [50, 51].
The primary objective of the trial is to show that
lapatinib-capecitabine radiochemotherapy is superior to
capecitabine radiochemotherapy. The choice of complete
pathologic response as the primary outcome measure
allows such interpretation since it is a feasible and re-
producible short-term endpoint and is reported to be as-
sociated with improved cancer-specific survival [7]. The
choice to use full doses for each treatment component
maximizes the probability of treatment response. As
with any novel treatment combination, tolerability will
be an important issue. The experimental arm has never
been studied in this setting. Therefore, we have inte-
grated into the Bayesian design a specific stopping rule
to address this. This rule was designed to reproduce the
performance of classic phase I trials, which are designed
to explore the maximum tolerated dose of a given agent
or combination while protecting as many patients as
possible from excessive risks. The main anticipated toxi-
city is diarrhea; therefore, mandatory pre-emptive anti-
diarrheal medication will be recommended for every
patient. Should excess toxicity be an issue with a standard
dose of lapatinib, we have stipulated a reset of the trial
with a lower dose of lapatinib. However, this should not
impact the assessment of clinical value of this combin-
ation, as the lower dose level of lapatinib is still associated
with a Cmin above that which is required for antitumor
effect. Additionally, the incorporation of a lead-in period
of lapatinib together with tumor sampling before and after
the 2-week lead-in period will provide further information
on the pharmacodynamics of lapatinib and direct evidence
of on-target effect.
This trial includes an exploratory biomarker program.
This was designed to better understand the role that
EGFR inhibitors and lapatinib in particular play in this
setting and to identify potentially predictive biomarkers
for response.
In conclusion, the LaRRC trial will inform on the role
of dual inhibition of EGFR and HER-2 in the neoadju-
vant treatment of resectable rectal cancer. The choice of
a Bayesian adaptive randomization together with an ini-
tial lead-in treatment phase with lapatinib in the experi-
mental arm provides the best chance to maximize the
information collected while effectively balancing the
risks and potential benefits for eligible patients.
Trial status
The trial is currently recruiting.
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